For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News

BREAKING NEWS
Nikhil Prasad  Fact checked by:Thailand Medical News Mar 13, 2024  8 months, 1 week, 2 days, 16 hours, 16 minutes ago

Med News: Pfizer’s Pregabalin That Is Used To Treat Anxiety And Neuropathic Pain Linked To Rising Drug Related Deaths!

2848 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
Med News: Pfizer’s Pregabalin That Is Used To Treat Anxiety And Neuropathic Pain Linked To Rising Drug Related Deaths!
Nikhil Prasad  Fact checked by:Thailand Medical News Mar 13, 2024  8 months, 1 week, 2 days, 16 hours, 16 minutes ago
Med News: In recent years, the commonly prescribed anxiety drug pregabalin has come under scrutiny due to a significant increase in linked fatalities. This surge in deaths, which more than doubled from 187 in 2018 to 441 in 2022 in England and Wales, has sparked concerns about the safety of this medication.
Death registrations related to Gabapentin or Pregabalin, England and Wales: 2018 and 2022 - Office for National Statistics

 
Pfizer’s Pregabalin Linked To Rising Drug Related Deaths

Med News coverages around the world shows that not only is Pregabalin linked to an increase of drug related deaths but also to a variety of adverse health issues.
 
https://metro.co.uk/2024/03/03/pregabalin-found-a-third-drug-related-deaths-20388624/
 
https://www.dailymail.co.uk/news/article-13154113/pregabalin-anti-depressant-anxiety-drug-effects.html
 
https://www.euronews.com/health/2024/03/07/if-i-miss-a-dose-i-have-trouble-breathing-anti-anxiety-drug-pregabalin-causes-concern-in-t
 
https://www.bbc.com/news/uk-northern-ireland-66579996
 
Unknown to many, Pregabalin was developed and its patents rights are actually owned by controversial American pharma giant: Pfizer through its subsidiary Warner-Lambert.
https://www.bmj.com/content/363/bmj.k4856
 
However, it is essential to examine the complex factors contributing to these deaths, including the potential for drug interactions, dependency, and the rise in pregabalin prescriptions.’
 
Pregabalin Overview
Pregabalin, known by brand names such as Lyrica and Alzain, was initially approved for use in Europe and the US in 2004. Widely prescribed to treat epilepsy, nerve pain, and anxiety, the drug has rewarding properties that can induce feelings of euphoria, calmness, and relaxation. While pregabalin itself is generally not considered dangerous, its potential side effects, including confusion and headaches, as well as the risk of dependence, warrant careful consideration.
 
The Danger of Drug Interactions
The key concern with pregabalin lies in its potential interactions with other drugs. Pregabalin, when com bined with opioids, certain sleep aids, benzodiazepines, muscle relaxants, and specific diabetes and epilepsy drugs, can lead to fatal outcomes. An analysis of pregabalin-related deaths in England from 2004 to 2020 revealed that over 90% of cases involved the presence of other opioids, often obtained illicitly. This highlights the critical need for educating prescribers and patients about potential risks and the importance of regular prescription reviews.
 
Rising Prescriptions and Fatalities
The recent increase in pregabalin-related deaths coincides with a surge in prescriptions, reaching 8.4 million in the UK alone in 2022, up from 5.5 million in 2016. This rise emphasizes the necessity for additional support to reduce patient risk, particularly concerning co-use with other drugs. Both prescribers and patients must be educated about the potential risks and dependency associated with pregabalin, fostering awareness of drug interactions and encouraging periodic prescription reviews.
 
Vulnerable Groups at Greater Risk
Certain groups, such as individuals with a history of substance use disorder, face a higher risk of harm from pregabalin. The lack of communication between mental health and drug treatment services may lead to potentially harmful drug interactions. Additionally, evidence suggests a growing problem of illicit pregabalin use in Europe and North America, further underscoring the need for awareness and support services.
 
The Human Side of the Issue
Beyond statistics, individual stories shed light on the challenges associated with pregabalin use. Personal accounts reveal the debilitating side effects and struggles with dependency. Users report a range of adverse effects, from panic attacks and extreme restlessness to depression and suicidal tendencies. Online support spaces, such as the "Lyrica Survivors" Facebook group, provide a platform for individuals to share their experiences and seek guidance on safely discontinuing pregabalin.
 
The Challenge of Dependency and Withdrawal
Dependency on pregabalin is a growing concern, with users facing challenges in discontinuing the medication. The drug's euphoric effects can lead to tolerance, requiring higher doses for the same sensation. Withdrawal symptoms, both physical and psychological, can be severe, impacting the quality of life for those attempting to taper off the medication.
 
Addressing Dependency Safely
As prescriptions for pregabalin continue to rise, there is a pressing need for support services to help individuals safely discontinue the medication. Gradual tapering, individualized approaches, and increased research into potential risk factors are crucial for addressing dependency effectively. Medical professionals must reevaluate short-term treatment approaches for mental health conditions, considering the long-term impact and potential risks associated with drugs like pregabalin.
 
Conclusion
The rise in pregabalin-related deaths calls for a comprehensive understanding of the factors contributing to this trend. While the drug itself is beneficial for many, its potential for dependency and fatal interactions with other drugs requires careful management. Education, awareness, and support services are crucial to ensuring the safe use and discontinuation of pregabalin. By addressing the complexities surrounding this medication, healthcare professionals can develop strategies to minimize harm and enhance patient safety.
 
For the latest Med News, keep on logging to Thailand Medical News.

MOST READ

Nov 05, 2024  18 days ago
Nikhil Prasad
Jul 25, 2024  4 months ago
Nikhil Prasad
Jul 24, 2024  4 months ago
Nikhil Prasad
Jun 10, 2023  1 year ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer